131 related articles for article (PubMed ID: 32782203)
1. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
Kallam A; Hansen N; Bierman P
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203
[No Abstract] [Full Text] [Related]
2. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
[No Abstract] [Full Text] [Related]
3. Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation.
Mahapatra S; Chin CC; Iagaru A; Heerema-McKenney A; Twist CJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2107-9. PubMed ID: 25066638
[TBL] [Abstract][Full Text] [Related]
4. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264
[No Abstract] [Full Text] [Related]
5. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Okahashi N; Uchihara M; Hoshino E
Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
[TBL] [Abstract][Full Text] [Related]
6. [Primary central nervous system post-transplant lymphoproliferative disorders].
Honda M; Koga M; Kanda T
Brain Nerve; 2014 Aug; 66(8):947-54. PubMed ID: 25082316
[TBL] [Abstract][Full Text] [Related]
7. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Marchesini G; Nadali G; Facchinelli D; Candoni A; Cattaneo C; Laurenti L; Fanci R; Farina F; Lessi F; Visentin A; Marchesi F; Prezioso L; Spolzino A; Tisi MC; Trastulli F; Picardi M; Verga L; Dargenio M; Busca A; Pagano L;
Br J Haematol; 2021 Apr; 193(2):316-324. PubMed ID: 33058237
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma.
Ginat DT; Purakal A; Pytel P
J Neurooncol; 2015 Nov; 125(2):297-305. PubMed ID: 26341369
[TBL] [Abstract][Full Text] [Related]
9. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758
[No Abstract] [Full Text] [Related]
10. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
12. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
Crane GM; Powell H; Kostadinov R; Rocafort PT; Rifkin DE; Burger PC; Ambinder RF; Swinnen LJ; Borowitz MJ; Duffield AS
Oncotarget; 2015 Oct; 6(32):33849-66. PubMed ID: 26460822
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
[TBL] [Abstract][Full Text] [Related]
14. EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system.
Xu H; Rewerska J; Aardsma N; Slavin K; Valyi-Nagy T; Ni H
Folia Neuropathol; 2017; 55(3):221-226. PubMed ID: 28984115
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation.
Nozzoli C; Bartolozzi B; Guidi S; Orsi A; Vannucchi AM; Leoni F; Bosi A
Leuk Lymphoma; 2006 Jan; 47(1):167-9. PubMed ID: 16321845
[TBL] [Abstract][Full Text] [Related]
16. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
George P; Brown A; Weinkove R
Pathology; 2020 Jun; 52(4):491-492. PubMed ID: 32349864
[No Abstract] [Full Text] [Related]
17. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Wang L; Li X; He YZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
[No Abstract] [Full Text] [Related]
18. Complete Response of a Young Woman With MYD88
Pabon CM; Neff JL; Forns TE; Wang J
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904
[No Abstract] [Full Text] [Related]
19. CSF IgH gene rearrangement analysis in isolated post-transplant lymphoproliferative disorder of the central nervous system.
Baehring JM; Landry ML; Cooper D; Hui P; Bannykh S
J Neurooncol; 2008 Jan; 86(1):57-60. PubMed ID: 17909942
[TBL] [Abstract][Full Text] [Related]
20. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Fowler NH; Nastoupil L; De Vos S; Knapp M; Flinn IW; Chen R; Advani RH; Bhatia S; Martin P; Mena R; Davis RE; Neelapu SS; Eckert K; Ping J; Co M; Beaupre DM; Neuenburg JK; Palomba ML
Br J Haematol; 2020 May; 189(4):650-660. PubMed ID: 32180219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
